Literature DB >> 27746969

Neither the maximum tumor size nor solid component size is prognostic in part-solid lung cancer: to be ground-glass opacity or not to be, is that really the question?

Kimihiro Shimizu1, Yoichi Ohtaki1, Seshiru Nakazawa1, Akira Mogi1, Hiroyuki Kuwano1.   

Abstract

Entities:  

Year:  2016        PMID： 27746969      PMCID： PMC5059323          DOI： 10.21037/jtd.2016.08.32

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung.

Authors:  Yukio Watanabe; Koji Tsuta; Masahiko Kusumoto; Akihiko Yoshida; Kenji Suzuki; Hisao Asamura; Hitoshi Tsuda
Journal:  Ann Thorac Surg       Date:  2013-11-06       Impact factor: 4.330

2.  Possible delayed cut-end recurrence after limited resection for ground-glass opacity adenocarcinoma, intraoperatively diagnosed as Noguchi type B, in three patients.

Authors:  Junji Yoshida; Genichiro Ishii; Tomoyuki Yokose; Keiju Aokage; Tomoyuki Hishida; Mitsuyo Nishimura; Takuya Onuki; Masayuki Noguchi; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2010-04       Impact factor: 15.609

3.  Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: a multicenter study.

Authors:  Yasuhiro Tsutani; Yoshihiro Miyata; Haruhiko Nakayama; Sakae Okumura; Shuji Adachi; Masahiro Yoshimura; Morihito Okada
Journal:  J Thorac Cardiovasc Surg       Date:  2011-11-20       Impact factor: 5.209

4.  Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis.

Authors:  Yuki Matsumura; Yuki Owada; Takumi Yamaura; Satoshi Muto; Jun Osugi; Mika Hoshino; Mitsunori Higuchi; Tetsuya Ohira; Hiroyuki Suzuki; Mitsukazu Gotoh
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-05-12

5.  Long-term outcome and late recurrence in patients with completely resected stage IA non-small cell lung cancer.

Authors:  Ryo Maeda; Junji Yoshida; Genichiro Ishii; Keiju Aokage; Tomoyuki Hishida; Mitsuyo Nishimura; Yutaka Nishiwaki; Kanji Nagai
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

6.  A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201).

Authors:  Kenji Suzuki; Teruaki Koike; Takashi Asakawa; Masahiko Kusumoto; Hisao Asamura; Kanji Nagai; Hirohito Tada; Tetsuya Mitsudomi; Masahiro Tsuboi; Taro Shibata; Haruhiko Fukuda; Harubumi Kato
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

7.  Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Authors:  Akihiko Yoshizawa; Shinji Sumiyoshi; Makoto Sonobe; Masashi Kobayashi; Masakazu Fujimoto; Fumi Kawakami; Tatsuaki Tsuruyama; William D Travis; Hiroshi Date; Hironori Haga
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

8.  EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.

Authors:  Toshimi Takano; Tomoya Fukui; Yuichiro Ohe; Koji Tsuta; Seiichiro Yamamoto; Hiroshi Nokihara; Noboru Yamamoto; Ikuo Sekine; Hideo Kunitoh; Koh Furuta; Tomohide Tamura
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

Authors:  Benjamin Izar; Lecia Sequist; Mihan Lee; Alona Muzikansky; Rebecca Heist; John Iafrate; Dora Dias-Santagata; Douglas Mathisen; Michael Lanuti
Journal:  Ann Thorac Surg       Date:  2013-08-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.